Use of cannabinoids in the treatment of epilepsy

Patent metadata

Field	Value
Publication number	US-2018228751-A1
Application number	US-201615751563-A
Country	US
Kind code	A1
Filing date	Jul 29, 2016
Priority date	Aug 10, 2015
Publication date	Aug 16, 2018
Grant date	—

Abstract

The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.

First claim

1 . A method of treating epilepsy in a subject, comprising administering to the subject a therapeutically effective amount of cannabidiolic acid (CBDA).

2 . The method according to claim 1 , wherein the epilepsy is a generalized epilepsy.

3 . The method according to claim 1 , wherein the epilepsy is characterized by tonic-clonic seizures.

4 . The method according to claim 1 , wherein the therapeutically effective amount is at least 0.1 mg.

5 . The method according to claim 1 , wherein the CBDA is in the form of a highly purified extract of cannabis such that the CBDA is present at greater than 98% of the total extract (w/w).

6 . The method according to claim 5 , wherein the highly purified extract comprises less than 1% (w/w) tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA).

7 . The method according to claim 1 , wherein the CBDA is synthetically produced.

8 . The method according to claim 1 , wherein the CBDA is administered concomitantly with one or more other cannabinoids.

9 . The method according to claim 8 , wherein the CBDA is used with cannabidiol (CBD).

10 . The method according to claim 9 , wherein the CBDA:CBD ratio is in the range of from 9:1 to 1:9 (CBDA:CBD).

11 . The method according to claim 1 , wherein the CBDA is administered concomitantly with one or more other anti-epileptic drugs (AED).

12 . The method according to claim 1 , wherein the CBDA is administered at a dose of less than 400 mg.

13 . The method according to claim 12 , wherein the CBDA is administered at a dose of from 1 mg to 100 mg.

14 - 15 . (canceled)

Assignees

• Gw Pharma Ltd

Inventors

• Stott Colin
• Jones Nicholas
• Williams Robin
• Whalley Benjamin

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• A61K36/3482

  Cannabis · CPC title

• A61K36/185

  Magnoliopsida (dicotyledons) · CPC title

• A61K31/192 Primary

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title